Following the Divestiture of Loss-Making Operations, Token Cat Limited Authorizes Its U.S. Subsidiary to Evaluate a Potential $ 500 Million Fundraising Plan for Nuclear Fission Research and M&A to Address the Growing Clean Energy Demand of AI Computing
BEIJING, Nov. 14, 2025 /PRNewswire/ -- Token Cat Limited (Nasdaq: TC) today announced…
Xinhua Silk Road: Unleashing digital potential to unlock new vitality of liquor industry
BEIJING, Oct. 31, 2025 /PRNewswire/ -- Amid the wave of the digital…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha…
CytoMed makes cash bid for potential acquisition of TC BioPharm Limiteds relevant assets
SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC)…
Indian CFOs prioritize digital transformation, emphasize strategic EPM-ERP connection to realize its full potential
Survey finds that modernizing operations, integrating fragmented systems and adopting intelligent planning…
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
